Key result
Endothelin 1 constricted afferent arterioles stronger than efferent arterioles, with ETA-R mediating vasoconstriction in both and ETB-R mediating constriction only in efferent arterioles.
ETA-R mediates vasoconstriction in afferent arterioles while ETB-R mediates basal NO release and constriction in efferent arterioles, suggesting a mechanism for ET-1 in kidney disease pathogenesis.
ET-1's differential arteriolar effects via ETA/ETB receptors may drive glomerular injury; animal data leave open targeted therapies in human CKD.
BACKGROUND: Endothelin 1 contributes to renal blood flow control and pathogenesis of kidney diseases. The differential effects, however, of endothelin 1 (ET-1) on afferent (AA) and efferent arterioles (EA) remain to be established. METHODS: We investigated endothelin type A and B receptor (ETA-R, ETB-R) functions in the control of AA and EA. Arterioles of ETB-R deficient, rescued mice [ETB(-/-)] and wild types [ETB(+/+)] were microperfused. RESULTS: ET-1 constricted AA stronger than EA in ETB(-/-) and ETB(+/+) mice. Results in AA: ET-1 induced similar constrictions in ETB(-/-) and ETB(+/+) mice. BQ-123 (ETA-R antagonist) inhibited this response in both groups. ALA-ET-1 and IRL1620 (ETB-R agonists) had no effect on arteriolar diameter. L-NAME did neither affect basal diameters nor ET-1 responses. Results in EA: ET-1 constricted EA stronger in ETB(+/+) compared to ETB(-/-). BQ-123 inhibited the constriction completely only in ETB(-/-). ALA-ET-1 and IRL1620 constricted only arterioles of ETB(+/+) mice. L-NAME decreased basal diameter in ETB(+/+), but not in ETB(-/-) mice and increased the ET-1 response similarly in both groups. The L-NAME actions indicate a contribution of ETB-R in basal nitric oxide (NO) release in EA and suggest dilatory action of ETA-R in EA. CONCLUSIONS: ETA-R mediates vasoconstriction in AA and contributes to vasoconstriction in EA in this mouse model. ETB-R has no effect in AA but mediates basal NO release and constriction in EA. The stronger effect of ET-1 on AA supports observations of decreased glomerular filtration rate to ET-1 and indicates a potential contribution of ET-1 to the pathogenesis of kidney diseases.
No takes yet. Share an insight, caveat, or question.
Schildroth et al. (2010) studied this question. Endothelin 1 (ET-1) vs. Wild type mice / basal conditions was evaluated on Arteriolar constriction. Endothelin 1 constricted afferent arterioles stronger than efferent arterioles, with ETA-R mediating vasoconstriction in both and ETB-R mediating constriction only in efferent arterioles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: